Chong Kun Dang Pharmaceutical (185750) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Chong Kun Dang Pharmaceutical stock KRW 63,555, price KRW 63,000, upside +0.9%, quality 35 out of 100. Rating: fairly valued. Calculated from audited financials with 16 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 5, 2026.
How to read this chart
60‑month range 59,800 KRW – 124,377 KRW · fair‑value band 61,009 KRW – 70,380 KRW · the 63,000 KRW price screens below the 63,555 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 5, 2026.
Follow Chong Kun Dang Pharmaceutical in your weekly email
Every Wednesday you see whether Chong Kun Dang Pharmaceutical is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Chong Kun Dang Pharmaceutical Corp. manufactures, markets, and sells medicines in South Korea and internationally.
Show moreShow less
It offers prescription drugs for anti-hypertension, anti-hyperlipidaemia, and anti-diabetics, as well as immunosuppressants; over-the-counter medicines; and consumer health products, such as insecticides and hair dye products, as well as health supplements.
The company was founded in 1941 and is headquartered in Seoul, South Korea.
Stock analysis
Chong Kun Dang Pharmaceutical (185750) currently trades at 63,000 KRW, while our model-based Fair Value estimate is 63,555 KRW, so the stock looks roughly fairly valued today (gap 0.9%).
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 115,734 KRW per share, and 9 of the 16 models we run sit above the 63,000 KRW price.
Bear case: the Dividend Discount group reads lowest at 15,284 KRW, and 7 of the 16 models stay below the price. Data coverage for this calculation is high.
Scenario range: 61,009 KRW (bear) to 70,380 KRW (bull), the price of 63,000 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 35/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Chong Kun Dang Pharmaceutical reported revenue of 1.7T KRW in FY2025 versus 1.3T KRW in FY2021, a compound +5.9%/yr. Reported net income was 77.5B KRW in FY2025, compounding +16.1%/yr from FY2021.
Key figures
Market cap 830B KRW (≈ $614M) Small · P/E ratio 10.4 · P/S ratio 0.47 · EPS (TTM) 6,032 KRW · Dividend yield 0.8% · Net margin 4.5% · Return on equity 8.2% · Return on assets (EBIT) 9.5% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 36 out of 100 (low confidence).
What moves the price
The share trades about 36% below its 52-week high and 5% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 1%, 185750 screens cheaper than that median.
Fair Value models
Bear61,009 KRWFair Value 63,555 KRWBull70,380 KRW
Price 63,000 KRW · Upside +0.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (4,744 KRW per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.38/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+6.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.4%
Start year 2020 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.2%
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+4.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year+3.4%
Dividend (yield on the price)0.8%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.10% → 5%
Compare Chong Kun Dang Pharmaceutical with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks
Beats the industry median on 8/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score35 · Bottom 25%
Fair Value upside+0.9% · Above median
Profitability
Return on equity (12 months)8.2% · Above median
Return on assets4.3% · Above median
Net margin (12 months)4.5% · Below median
Operating margin (12 months)3.9% · Below median
Growth and dividend
Revenue growth (quarter YoY)10.0% · Above median
Dividend yield (12 months)0.8% · Below median
Balance sheet
Debt / equity0.19× · Above median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Chong Kun Dang Pharmaceutical Fair Value". https://www.fairvalue-calculator.com/stock/185750
Frequently asked questions
Is Chong Kun Dang Pharmaceutical (185750) overvalued or undervalued?
As of Nov 5, 2026, our model estimates a fair value of 63,555 KRW versus a price of 63,000 KRW, about +1% upside (fairly valued).
What is the fair value of 185750?
Our model-based fair value for Chong Kun Dang Pharmaceutical is 63,555 KRW (as of Nov 5, 2026), built from audited fundamentals. The current price: 63,000 KRW.
What is the quality score of 185750?
Chong Kun Dang Pharmaceutical has a Quality Score of 35/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Chong Kun Dang Pharmaceutical (185750)?
Our model-based price target is the fair value of 63,555 KRW (as of Nov 5, 2026) from 16 valuation models. Cautious scenario 61,009 KRW, optimistic scenario 70,380 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Chong Kun Dang Pharmaceutical stock forecast for 2026?
Our models put fair value at 63,555 KRW, about +1% upside versus a price of 63,000 KRW (fairly valued). Cautious scenario 61,009 KRW, optimistic scenario 70,380 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Chong Kun Dang Pharmaceutical (185750)?
Chong Kun Dang Pharmaceutical reported trailing-twelve-month revenue of about 1.8T KRW (latest available figure, as of Nov 5, 2026).
Does Chong Kun Dang Pharmaceutical pay a dividend?
Chong Kun Dang Pharmaceutical currently shows a dividend yield of 0.79% relative to its recent price (as of Nov 5, 2026).
How much is the dividend of Chong Kun Dang Pharmaceutical (185750) and when is the ex-dividend date?
Chong Kun Dang Pharmaceutical pays a dividend of 500.00 KRW per share a year, a dividend yield of 0.8%. The last ex-dividend date was Dec 29, 2025. A dividend has been paid every year since at least 2013. The payout ratio is 8.3% of earnings. Our assessment: Token dividend. At a yield of 0.8% the dividend is symbolic. On paper it is not fully covered by earnings or free cash flow, but at this size that hardly matters: even scrapping it entirely would cost less than 0.8% a year, and coverage ratios on amounts this small swing with ordinary working-capital movements. Judge this company on its business, not on its dividend.
What is the intrinsic value of Chong Kun Dang Pharmaceutical (185750)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Chong Kun Dang Pharmaceutical it is 63,555 KRW per share (as of Nov 5, 2026), against a price of 63,000 KRW. It is the blended result of 16 valuation models in 6 families (Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Chong Kun Dang Pharmaceutical stock overvalued or undervalued in 2026?
As of Nov 5, 2026, 185750 trades below its calculated fair value: price 63,000 KRW, fair value 63,555 KRW, a gap of about +1% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 185750?
No. The price is what the market pays today (63,000 KRW); the fair value is what the company's own numbers justify (63,555 KRW). For Chong Kun Dang Pharmaceutical the two are 555.00 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Chong Kun Dang Pharmaceutical worth?
The market values Chong Kun Dang Pharmaceutical at about 830B KRW (market capitalisation, as of Nov 5, 2026). Per share that is 63,000 KRW; our models calculate a fair value of 63,555 KRW per share.
What do the bullish and bearish scenarios say about 185750?
Our models span a range for Chong Kun Dang Pharmaceutical: cautious scenario 61,009 KRW, base 63,555 KRW, optimistic 70,380 KRW per share (as of Nov 5, 2026, price 63,000 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 185750?
Chong Kun Dang Pharmaceutical trades at a price-to-earnings ratio of 10.4 (as of Nov 5, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 63,555 KRW is built from several models across several years. Other multiples: P/B 0.8, P/S 0.5, EV/EBITDA 6.6.
How solid is the balance sheet of Chong Kun Dang Pharmaceutical (185750)?
Balance-sheet figures for Chong Kun Dang Pharmaceutical (as of Nov 5, 2026): return on equity 8.2%, debt of 0.19 per unit of equity. They feed the Quality Score of 35/100, which measures business quality independently of the share price.
How far is 185750 from its 52-week high?
Chong Kun Dang Pharmaceutical trades at 63,000 KRW, about 36% below its 52-week high of 97,700 KRW and 5% above the low of 59,800 KRW (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 63,555 KRW is for.
Which stocks are comparable to Chong Kun Dang Pharmaceutical?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Chong Kun Dang Pharmaceutical stock attractive at the current price?
The data as of Nov 5, 2026: price 63,000 KRW, calculated fair value 63,555 KRW (+1%), Quality Score 35/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 185750 calculated?
We run Chong Kun Dang Pharmaceutical through 16 models from 6 families: Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 63,555 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Chong Kun Dang Pharmaceutical currently trades 1% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Chong Kun Dang Pharmaceutical (185750)?
The closing price on Nov 6, 2026 was 63,000 KRW. Our model-based fair value is 63,555 KRW, about +1% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Chong Kun Dang Pharmaceutical right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. The price sits in the lower half of our model range, the side with the larger margin of safety. The data supports the verdict: every model runs on fully documented inputs.
Key figures of Chong Kun Dang Pharmaceutical
How large is the market capitalisation of Chong Kun Dang Pharmaceutical (185750)?
The market capitalisation of Chong Kun Dang Pharmaceutical is 830B KRW (≈ $614M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Chong Kun Dang Pharmaceutical (185750)?
The price-to-sales ratio of Chong Kun Dang Pharmaceutical is 0.47 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Chong Kun Dang Pharmaceutical (185750)?
Earnings per share at Chong Kun Dang Pharmaceutical are 6,032 KRW (price ÷ EPS = P/E 10.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Chong Kun Dang Pharmaceutical (185750)?
The dividend yield of Chong Kun Dang Pharmaceutical is 0.8% (payout 8.3%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Chong Kun Dang Pharmaceutical (185750)?
The net margin of Chong Kun Dang Pharmaceutical is 4.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Chong Kun Dang Pharmaceutical (185750)?
The return on equity (ROE) of Chong Kun Dang Pharmaceutical is 8.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Chong Kun Dang Pharmaceutical (185750)?
On an EBIT basis the return on assets of Chong Kun Dang Pharmaceutical is 9.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Chong Kun Dang Pharmaceutical (185750)?
The operating margin of Chong Kun Dang Pharmaceutical is 3.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Chong Kun Dang Pharmaceutical (185750)?
Revenue at Chong Kun Dang Pharmaceutical is growing +10.0% versus a year earlier (3y avg +4.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Chong Kun Dang Pharmaceutical (185750)?
Earnings per share at Chong Kun Dang Pharmaceutical are growing +4.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Chong Kun Dang Pharmaceutical (185750) generate?
The free cash flow of Chong Kun Dang Pharmaceutical is −112B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Chong Kun Dang Pharmaceutical (185750) carry?
The net debt of Chong Kun Dang Pharmaceutical is 142B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Chong Kun Dang Pharmaceutical in the live analysis
One click puts Chong Kun Dang Pharmaceutical on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 5, 2026